European Archives - Page 53 of 1166 - European Medical Journal

Is AI Safe and Effective in T2D Insulin Titration?

AI safely matches senior doctors in hospital insulin dosing for T2D, easing clinical load without compromising care.

Lanadelumab Reduces HAE Attacks in Adolescent Patients

The analysis demonstrated significant reductions in HAE attacks among adolescent patients.

Aspirin Cessation Unnecessary After Surgically Treated Chronic Subdural Haematoma

Aspirin cessation fails to cut cSDH recurrence post-surgery, trial reveals.

Genetic Profiles Influence Idiopathic Pulmonary Fibrosis Survival

Rare genetic variants and common polygenic risk scores independently influence survival in idiopathic pulmonary fibrosis.

Sjögren Disease Tied to 70% Higher Mortality Risk

A decade-long study has found that people with Sjögren disease are 70% more likely to die than the general population, with infections, cancer, and cardiovascular disease as the top causes.

Longevity Medicine

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease.

Personalised Lighting Intervention Eases Fatigue in Patients with Cancer

A study involving 138 cancer patients found that a personalised lighting intervention, guided by wearable-tracked circadian rhythms, reduced fatigue and improved sleep, anxiety, and physical function.

New air cargo project links medicine and agriculture

The initiative is set to revolutionise healthcare delivery and agricultural exports in low- and middle-income countries.

Stark Inequalities in Infectious Disease Admissions Revealed

A new report from the UK Health Security Agency (UKHSA) highlights profound inequalities in infectious disease outcomes and hospital admissions across England.

Nutrition and Diabetes Policies Help Combat MASLD: EASL 2025

Timely public health policies targeting key metabolic conditions can reduce the global burden of MASLD.